ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Mitochondrial Localization of Cx26 Promotes Colorectal Cancer Malignancy and Exposes a Fatal Vulnerability to Drug Targeting.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The malignant progression of colorectal cancer (CRC) is closely linked to metastasis and therapy resistance, but underlying mechanisms remain unclear. Here, we identify mitochondrial translocation of connexin 26 (Cx26) as a hallmark of highly malignant metastatic CRC and reveal its critical role in promoting ER-mitochondria crosstalk, calcium signaling, and epithelial-mesenchymal transition (EMT). Mechanistically, we demonstrate that protein L-isoaspartyl/D-aspartyl O-methyltransferase (PIMT) methylates Cx26 at asparagine 176, enhancing its mitochondrial localization and stability. This modification disrupts Cx26's gap junction function while activating calcium signaling to drive EMT and metastasis. Furthermore, we discovered that bortezomib (BTZ), contrary to its canonical proteasome inhibition mechanism, exhibits exceptional efficacy against highly malignant CRC by targeting the PIMT-Cx26 axis. BTZ directly binds PIMT, further amplifying Cx26 mitochondrial translocation and hyperactivating Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.